Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Mid and smallcaps outperform
Fri, 17 May 11:30 am

Indian equity markets fell into the red after opening on a flat note earlier today. Sectoral indices traded mixed with consumer durables and healthcare stocks witnessing maximum losses while realty and power stocks witnessed maximum gains.

The BSE-Sensex is trading lower by 12 points and NSE-Nifty is trading down by 6 points. However, BSE Mid Cap and BSE Small Cap indices are trading up by 0.3% and 0.4% respectively. The rupee is trading at 54.88 to the US dollar.

Engineering stocks are trading mixed with Everest Kanto Cylinders and Manugraph India leading the gains while TRF Limited and Kalpataru Power are witnessing maximum losses. As per a leading daily, Larsen & Toubro (L&T) has won new contracts worth Rs 25 bn in April and May. These contracts are for various business segments. While the building and factories segment has won orders of Rs 10 bn, the heavy civil infrastructure business has secured orders for the Kochi metro rail worth Rs 8.6 bn. L&T's transportation infrastructure segment has secured an order from Dedicated Freight Corridor Corporation of India Limited worth Rs 3.1 bn towards double tracking of a railway line between New Karwandiya to Durgauti section of the eastern corridor. Also, water and renewable energy business has received Rs 1.5 bn worth of order from the Public Health Engineering Department for water supply distribution. Besides, orders worth Rs 1.9 bn have been obtained for a project under the power business.

Pharma stocks are trading weak led by Glenmark Pharma and Piramal Enterprises. As per a leading daily, the Government of India has decided to bring down the prices of essential medicines as per the new norms in pharma industry. Also, the norms call for increasing the number of drugs under price control and change the method of regulating the prices. The new regime would be effective 45 days from now and the government would regulate the prices of 652 medicines. Earlier this number stood at only 74. We may note here that the new pricing regime would replace the 18 year old method of fixing prices on a cost-plus basis. Drugs will now be priced as per market price-linked cap for each drug.

The new norms are likely to impact the business of both Indian as well as multinational pharma companies. However, makers of niche drugs may not get affected. As per the industry experts, the companies that are likely to get hit are Glaxosmithkline, Sanofi Aventis, Cipla and Cadila.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Mid and smallcaps outperform". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.